OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Functional immune responses against SARS-CoV-2 variants of concern after fourth COVID-19 vaccine dose or infection in patients with blood cancer
Annika Fendler, Scott T.C. Shepherd, Lewis Au, et al.
Cell Reports Medicine (2022) Vol. 3, Iss. 10, pp. 100781-100781
Open Access | Times Cited: 22
Annika Fendler, Scott T.C. Shepherd, Lewis Au, et al.
Cell Reports Medicine (2022) Vol. 3, Iss. 10, pp. 100781-100781
Open Access | Times Cited: 22
Showing 22 citing articles:
mRNA Vaccines against SARS-CoV-2: Advantages and Caveats
Miriam Echaide, Luisa Chocarro, Ana Bocanegra, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 6, pp. 5944-5944
Open Access | Times Cited: 51
Miriam Echaide, Luisa Chocarro, Ana Bocanegra, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 6, pp. 5944-5944
Open Access | Times Cited: 51
Additive effects of booster mRNA vaccination and SARS-CoV-2 Omicron infection on T cell immunity across immunocompromised states
Thomas Müller, Takuya Sekine, Darya Trubach, et al.
Science Translational Medicine (2023) Vol. 15, Iss. 704
Open Access | Times Cited: 20
Thomas Müller, Takuya Sekine, Darya Trubach, et al.
Science Translational Medicine (2023) Vol. 15, Iss. 704
Open Access | Times Cited: 20
Neutralizing antibodies to Omicron after the fourth SARS-CoV-2 mRNA vaccine dose in immunocompromised patients highlight the need of additional boosters
María Rescigno, Chiara Agrati, Carlo Salvarani, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 15
María Rescigno, Chiara Agrati, Carlo Salvarani, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 15
Accurate evaluation of live-virus microneutralisation for SARS-CoV-2 variant JN.1 in the assessment of vaccination and therapeutics
Giulia Dowgier, Agnieszka Hobbs, David Greenwood, et al.
Vaccine (2025) Vol. 54, pp. 126960-126960
Closed Access
Giulia Dowgier, Agnieszka Hobbs, David Greenwood, et al.
Vaccine (2025) Vol. 54, pp. 126960-126960
Closed Access
SARS-CoV-2-Specific T Cell Responses in Immunocompromised Individuals with Cancer, HIV or Solid Organ Transplants
David B. Reeg, Maike Hofmann, Christoph Neumann‐Haefelin, et al.
Pathogens (2023) Vol. 12, Iss. 2, pp. 244-244
Open Access | Times Cited: 14
David B. Reeg, Maike Hofmann, Christoph Neumann‐Haefelin, et al.
Pathogens (2023) Vol. 12, Iss. 2, pp. 244-244
Open Access | Times Cited: 14
COVID-19 Vaccination in Patients With Cancer and Patients Receiving HSCT or CAR-T Therapy: Immune Response, Real-World Effectiveness, and Implications for the Future
Victoria Hall, Benjamin W. Teh
The Journal of Infectious Diseases (2023) Vol. 228, Iss. Supplement_1, pp. S55-S69
Open Access | Times Cited: 11
Victoria Hall, Benjamin W. Teh
The Journal of Infectious Diseases (2023) Vol. 228, Iss. Supplement_1, pp. S55-S69
Open Access | Times Cited: 11
Main and papain-like proteases as prospective targets for pharmacological treatment of coronavirus SARS-CoV-2
Larysa V. Yevsieieva, Kateryna Lohachova, Alexander Kyrychenko, et al.
RSC Advances (2023) Vol. 13, Iss. 50, pp. 35500-35524
Open Access | Times Cited: 9
Larysa V. Yevsieieva, Kateryna Lohachova, Alexander Kyrychenko, et al.
RSC Advances (2023) Vol. 13, Iss. 50, pp. 35500-35524
Open Access | Times Cited: 9
Oral antivirals for COVID-19 among patients with cancer
Dorra Guermazi, Panos Arvanitis, Kendra Vieira, et al.
Supportive Care in Cancer (2024) Vol. 32, Iss. 8
Closed Access | Times Cited: 2
Dorra Guermazi, Panos Arvanitis, Kendra Vieira, et al.
Supportive Care in Cancer (2024) Vol. 32, Iss. 8
Closed Access | Times Cited: 2
Outpatient anti-spike monoclonal antibody administration is associated with decreased morbidity and mortality among patients with cancer and COVID-19
Panos Arvanitis, Alexis Hope Lerner, Kendra Vieira, et al.
Clinical and Experimental Medicine (2023) Vol. 23, Iss. 6, pp. 2739-2748
Open Access | Times Cited: 5
Panos Arvanitis, Alexis Hope Lerner, Kendra Vieira, et al.
Clinical and Experimental Medicine (2023) Vol. 23, Iss. 6, pp. 2739-2748
Open Access | Times Cited: 5
Sotrovimab restores neutralization against current Omicron subvariants in patients with blood cancer
Mary Wu, Scott T.C. Shepherd, Annika Fendler, et al.
Cancer Cell (2023) Vol. 41, Iss. 5, pp. 821-823
Open Access | Times Cited: 5
Mary Wu, Scott T.C. Shepherd, Annika Fendler, et al.
Cancer Cell (2023) Vol. 41, Iss. 5, pp. 821-823
Open Access | Times Cited: 5
Humoral and cellular responses to SARS‐CoV ‐2 in patients with B‐cell haematological malignancies improve with successive vaccination
Christopher L. Pinder, Dylan Jankovic, Thomas A. Fox, et al.
British Journal of Haematology (2023) Vol. 202, Iss. 6, pp. 1091-1103
Open Access | Times Cited: 5
Christopher L. Pinder, Dylan Jankovic, Thomas A. Fox, et al.
British Journal of Haematology (2023) Vol. 202, Iss. 6, pp. 1091-1103
Open Access | Times Cited: 5
Oral antivirals for COVID-19 among patients with cancer
Dorra Guermazi, Panos Arvanitis, Kendra Vieira, et al.
Research Square (Research Square) (2024)
Open Access | Times Cited: 1
Dorra Guermazi, Panos Arvanitis, Kendra Vieira, et al.
Research Square (Research Square) (2024)
Open Access | Times Cited: 1
Effectiveness and safety of COVID-19 vaccination in people with blood cancer
Emma Copland, Jennifer Hirst, Emma Mi, et al.
European Journal of Cancer (2024) Vol. 201, pp. 113603-113603
Open Access | Times Cited: 1
Emma Copland, Jennifer Hirst, Emma Mi, et al.
European Journal of Cancer (2024) Vol. 201, pp. 113603-113603
Open Access | Times Cited: 1
The immunologic outcomes and adverse events of COVID-19 vaccine booster dose in immunosuppressed people: A systematic review
SeyedAhmad SeyedAlinaghi, Mohsen Dashti, Arian Afzalian, et al.
Preventive Medicine Reports (2024) Vol. 44, pp. 102778-102778
Open Access | Times Cited: 1
SeyedAhmad SeyedAlinaghi, Mohsen Dashti, Arian Afzalian, et al.
Preventive Medicine Reports (2024) Vol. 44, pp. 102778-102778
Open Access | Times Cited: 1
Re‐vaccination against SARS ‐CoV‐2 in allogeneic HSCT patients: Repeated primary vaccine doses increase seroconversion rates
Marios Tsoutsoukis, Chloe Anthias, Sandra Easdale, et al.
British Journal of Haematology (2024)
Closed Access | Times Cited: 1
Marios Tsoutsoukis, Chloe Anthias, Sandra Easdale, et al.
British Journal of Haematology (2024)
Closed Access | Times Cited: 1
Comprehensive humoral and cellular immune responses to COVID-19 vaccination in adults with cancer
Amy Body, Luxi Lal, Sriganesh Srihari, et al.
Vaccine (2024), pp. 126547-126547
Open Access | Times Cited: 1
Amy Body, Luxi Lal, Sriganesh Srihari, et al.
Vaccine (2024), pp. 126547-126547
Open Access | Times Cited: 1
Lower T cell response against SARS-CoV-2 variants of concern after mRNA vaccine and risk of breakthrough infections in people with HIV
José L. Casado, Pilar Vizcarra, Sara Martín-Colmenarejo, et al.
AIDS (2023) Vol. 37, Iss. 6, pp. 877-882
Open Access | Times Cited: 3
José L. Casado, Pilar Vizcarra, Sara Martín-Colmenarejo, et al.
AIDS (2023) Vol. 37, Iss. 6, pp. 877-882
Open Access | Times Cited: 3
Dynamics of humoral and cellular response to three doses of anti-SARS-CoV-2 BNT162b2 vaccine in patients with hematological malignancies and older subjects
Valentina Laquintana, Carla Mottini, Francesco Marchesi, et al.
Frontiers in Immunology (2024) Vol. 14
Open Access
Valentina Laquintana, Carla Mottini, Francesco Marchesi, et al.
Frontiers in Immunology (2024) Vol. 14
Open Access
Accurate evaluation of live-virus microneutralisation for SARS-CoV-2 variant JN.1
Giulia Dowgier, Agnieszka Hobbs, David Greenwood, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access
Giulia Dowgier, Agnieszka Hobbs, David Greenwood, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access
Neutralizing antibodies to Omicron after the fourth SARS-CoV-2 mRNA vaccine dose in immunocompromised patients highlight the need of additional boosters
María Rescigno, Chiara Agrati, Carlo Salvarani, et al.
medRxiv (Cold Spring Harbor Laboratory) (2022)
Open Access | Times Cited: 1
María Rescigno, Chiara Agrati, Carlo Salvarani, et al.
medRxiv (Cold Spring Harbor Laboratory) (2022)
Open Access | Times Cited: 1
Outpatient anti-spike monoclonal antibody administration is associated with decreased morbidity and mortality among patients with cancer and COVID-19
Panos Arvanitis, Alexis Hope Lerner, Kendra Vieira, et al.
Research Square (Research Square) (2023)
Open Access
Panos Arvanitis, Alexis Hope Lerner, Kendra Vieira, et al.
Research Square (Research Square) (2023)
Open Access
Respuesta inmunológica a la vacunación y riesgo de COVID-19 en adultos con neoplasias hematológicas
Jorge Alberto Cortés, Laura Cristina Nócua-Báez, Cándida Díaz‐Brochero, et al.
Revista chilena de infectología (2023) Vol. 40, Iss. 3, pp. 228-235
Open Access
Jorge Alberto Cortés, Laura Cristina Nócua-Báez, Cándida Díaz‐Brochero, et al.
Revista chilena de infectología (2023) Vol. 40, Iss. 3, pp. 228-235
Open Access
The response to BTN62b2 booster doses demonstrates that serum antibodies do not predict the establishment of immune B-cell memory in common variable immune deficiencies
Eva Piano Mortari, Federica Pulvirenti, Valentina Marcellini, et al.
medRxiv (Cold Spring Harbor Laboratory) (2022)
Open Access
Eva Piano Mortari, Federica Pulvirenti, Valentina Marcellini, et al.
medRxiv (Cold Spring Harbor Laboratory) (2022)
Open Access
